Menu

Tucatinib Overview: HER2-Positive Breast Cancer and RAS Wild-Type Colorectal Cancer Dosing, Brain Metastases Data and Safety

Author: medicalhalo
Release time: 2026-11-16 03:10:55

  Tucatinib(Tukysa)is an oral small-molecule HER2 tyrosine kinase inhibitor.It acts on the intracellular HER2 kinase domain and reduces downstream proliferative signaling.Compared with broader pan-HER/EGFR inhibitors,it is more HER2-selective,so EGFR-driven rash is usually less prominent.It penetrates the central nervous system,which is why it is studied in HER2-positive breast cancer with brain metastases.

  1.Different HER2 Logic in Breast and Colorectal Cancer

  HER2 overexpression or amplification drives tumor growth.In breast cancer,HER2 positivity occurs in about 15%—20%;major challenges include multiline resistance and brain metastases.In colorectal cancer,HER2 amplification is only about 2%—5%,but it is a actionable target in RAS wild-type disease.If RAS is mutated,tumors may bypass HER2 signaling,so HER2-only inhibition is less useful.Indication rules,companion testing and combination choices therefore differ by tumor type.

  2.Indications and Combinations

  HER2-positive unresectable/metastatic breast cancer:tucatinib+trastuzumab+capecitabine for adults who received at least one prior anti-HER2 regimen in the metastatic setting;the indication explicitly includes patients with brain metastases.

  RAS wild-type,HER2-positive unresectable/metastatic colorectal cancer:tucatinib+trastuzumab after disease progression on fluoropyrimidine-,oxaliplatin-and irinotecan-based chemotherapy;confirm HER2 overexpression/amplification and RAS wild-type status before starting.

  Testing notes:breast cancer uses IHC and ISH when IHC is 2+;colorectal HER2 scoring is stricter and must be interpreted together with RAS and other molecular markers rather than by breast criteria alone.

  3.Key Trial Data

  HER2CLIMB(breast):tucatinib plus trastuzumab and capecitabine versus placebo plus the same two drugs showed median PFS 7.8 vs 5.6 months,median OS 21.9 vs 17.4 months,ORR about 40.6%vs 22.8%,and in stable brain metastases PFS 7.6 vs 5.4 months.

  MOUNTAINEER(colorectal):tucatinib plus trastuzumab showed ORR about 38.1%,median duration of response about 12.4 months and median PFS about 8.2 months.The two trials differ in tumor type,prior therapy and combinations,so numbers should not be compared head-to-head.

  4.Dosing and Administration

  Standard dose is 300mg orally twice daily,whole tablets,not chewed or split,about 12 hours apart and at consistent times,with or without food.With capecitabine,the typical capecitabine dose is 1000mg/m²twice daily on days 1—14 of each 21-day cycle,taken within 30 minutes after a meal.If a dose is missed or vomited,do not make up the dose;take the next scheduled dose.Stop or modify therapy for disease progression or unacceptable toxicity.Severe hepatic impairment may start at 200mg twice daily;adverse-event reductions may go to 250,200 and 150mg twice daily,and discontinue if 150mg twice daily is not tolerable.

  5.Adverse Reactions and Management

  Common issues include diarrhea,nausea,vomiting,stomatitis,decreased appetite,fatigue,rash,palmar-plantar erythrodysesthesia,transaminase/bilirubin increases and anemia;capecitabine adds hand-foot reactions.

  Diarrhea:hydrate and use antidiarrheals for mild cases;hold tucatinib and seek care for severe,bloody,dehydrating or feed-intolerant diarrhea.

  Hepatotoxicity:baseline and periodic ALT,AST and bilirubin;evaluate jaundice,dark urine or right-upper-quadrant pain promptly.

  Brain metastases:follow scheduled intracranial imaging;do not self-discontinue because symptoms improve.

  Pregnancy/lactation:embryo-fetal risk;effective contraception per labeling and avoid breastfeeding.

  6.Interactions and Special Populations

  Tucatinib is mainly metabolized via CYP2C8 and partly via CYP3A.Avoid strong CYP2C8 inhibitors;reduce tucatinib if unavoidable.Avoid strong CYP3A inducers and moderate CYP2C8 inducers.Use caution with narrow-therapeutic-index CYP3A or P-gp substrates.Mild-to-moderate hepatic impairment is evaluated individually;severe impairment uses a lower starting dose.Renal concerns are mainly relevant when combined with capecitabine,and dosing follows the full labeling.

  

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。

Tucatinib
描述
Tucatinib significantly enhances its anti-tumor effect by combining with other drugs such as trastuzumab, providing a new treatment option for patient [ 详情 ]
微信在线客服